You have read all your free articles, to continue reading subscribe to read the rest of this content.
Oncopeptides has announced updated results and safety measures based on the head-to-head phase 3 OCEAN study evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in patients with relapsed refractory multiple myeloma who have received 2 – 4 priorAlready a subscriber Login You have read all…
The company has received authorization to conduct a phase I/II clinical study on the quadrivalent influenza vaccine candidate Immunose FLU, a novel nose drop formulation based on the company´s technology Endocine and inactivated split antigens. Eurocine Vaccines submitted applications to the SweAlready a subscriber Login You have read all your…
The first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating Nektar’s CD122-preferential IL-2 pathway agonist with Vaccibody's personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). “We’re pleAlready a subscriber Login You have read all your…
An AstraZeneca drug with disappointing results against solid tumors has shown promise in the treatment of Alzheimer’s disease, according to a team at Yale University in the U.S. The drug, AZD0530, attacks one of the key steps in the development of Alzheimer's--blocking the activation of the enzAlready a subscriber Login…
